Itch is the lead symptom of atopic dermatitis (AD), impacting sleep and quality of life (QoL), and is a key component of scales assessing patient reported AD severity. Here, we report the effect of baricitinib (BARI), an oral, selective Janus kinase (JAK) 1 and 2 inhibitor, on frequency and severity of itch and sleep disturbance, and the correlation between improvements in these parameters with QoL over 16 weeks in patients from BREEZE-AD4.
Moderate-to-severe plaque psoriasis is a chronic immune-mediated disorder with significant impact on quality of life. Ixekizumab is a specific inhibitor of IL-17A, a main driver cytokine in Ps pathogenesis. IXE has shown high levels of efficacy in clinical trials.